Home NDC 70518-3099-1 NDC 70518-3099-1 - Ceftriaxone Sodium This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
Product NDC 70518-3099
Requested NDC 70518-3099-1
Package NDCs from labels 70518-3099-1, 70518-3099-0
Manufacturer REMEDYREPACK INC.
Effective date 2021-12-23
Current FDA listing Not matched in FDA.report NDC product tables DailyMed Labels# Label, Manufacturer, Effective date table Label Manufacturer Effective date Type Ceftriaxone for Injection, USP REMEDYREPACK INC. 2021-12-23 HUMAN PRESCRIPTION DRUG LABEL
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 2 of 2 · 35 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Ceftriaxone Sodium CEFTRIAXONE SODIUM A-S Medication Solutions 1aa0a4ee-1b39-4c3d-a7a3-33dded6fe28c 2024-01-31 Warnings, Adverse reactions Exact identifier rxcui: 309092 unii: 023Z5BR09K Ceftriaxone Sodium CEFTRIAXONE SODIUM A-S Medication Solutions ff8e830a-c288-46fb-9e19-ec2017943c07 2024-01-31 Warnings, Adverse reactions Exact identifier rxcui: 309092 unii: 023Z5BR09K ceftriaxone CEFTRIAXONE Sagent Pharmaceuticals 5cf93bc5-9e4c-4734-bc02-c7d0ac071022 2023-11-08 Warnings, Adverse reactions Exact identifier rxcui: 1665046 rxcui: 1665005 rxcui: 1665021 unii: 023Z5BR09K Ceftriaxone CEFTRIAXONE Fresenius Kabi USA, LLC 7ea1db43-40fa-417b-8911-ae98092070a0 2023-09-30 Warnings, Adverse reactions Exact identifier rxcui: 1665046 rxcui: 1665005 rxcui: 1665021 unii: 023Z5BR09K Ceftriaxone Sodium CEFTRIAXONE SODIUM Asclemed USA, Inc. f01cf0e5-caaf-4759-ba21-50f3aceff523 2023-09-02 Warnings, Adverse reactions Exact identifier application number: ANDA203702 rxcui: 1665005 unii: 023Z5BR09K Ceftriaxone Sodium CEFTRIAXONE SODIUM Apotex Corp. 5116231f-82d1-44be-b08e-560c9a50e5c5 2023-08-31 Warnings, Adverse reactions Exact identifier application number: ANDA203702 ndc (product): 60505-6148 rxcui: 1665046 rxcui: 1665005 rxcui: 309092 rxcui: 1665021 spl id: 0432e6c3-ad77-726c-e063-6294a90a798c spl set id: 5116231f-82d1-44be-b08e-560c9a50e5c5 unii: 023Z5BR09K Ceftriaxone Sodium CEFTRIAXONE SODIUM Apotex Corp. ac03a72c-0e35-40f9-b7fc-081badb5f19c 2023-01-28 Warnings, Adverse reactions Exact identifier unii: 023Z5BR09K Ceftriaxone CEFTRIAXONE SODIUM Samson Medical Technologies, LLC 5cd2d96f-83e5-4326-ae87-d0ede4ba493a 2023-01-15 Warnings, Adverse reactions Exact identifier unii: 023Z5BR09K Ceftriaxone CEFTRIAXONE Proficient Rx LP fcf401df-bcdc-4773-a63b-9741c0f74b3d 2022-11-01 Warnings, Adverse reactions Exact identifier rxcui: 1665046 unii: 023Z5BR09K Ceftriaxone Sodium CEFTRIAXONE SODIUM Proficient Rx LP a25ab5ea-c46d-4562-8f7e-0ccffc2ab069 2022-10-01 Warnings, Adverse reactions Exact identifier rxcui: 1665046 unii: 023Z5BR09K e4e1f495-bfbc-a4a6-e053-2995a90affe8 a981f45d-6330-403e-a490-b438cf8753f7 2022-07-28 Warnings, Adverse reactions Exact identifier spl set id: a981f45d-6330-403e-a490-b438cf8753f7 Ceftriaxone Sodium CEFTRIAXONE SODIUM Proficient Rx LP 42ba7a9d-7d2b-4eac-af59-897151a8c924 2022-05-02 Warnings, Adverse reactions Exact identifier application number: ANDA203702 rxcui: 1665021 unii: 023Z5BR09K Ceftriaxone Sodium CEFTRIAXONE SODIUM Hospira, Inc 9d1f630b-e759-4395-9d01-ddc90e4fea75 2022-03-09 Warnings, Adverse reactions Exact identifier rxcui: 1665046 rxcui: 1665021 unii: 023Z5BR09K CEFTRIAXONE AND DEXTROSE CEFTRIAXONE B. Braun Medical Inc. 67153914-16bc-490d-82d7-638061618467 2022-01-13 Warnings, Adverse reactions Exact identifier rxcui: 1665046 rxcui: 1665021 unii: 023Z5BR09K Ceftriaxone CEFTRIAXONE Hikma Pharmaceuticals USA Inc. 1f8776bd-4f5b-427a-849a-6b8338f7997d 2019-04-24 Warnings, Adverse reactions Exact identifier unii: 023Z5BR09K
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.